Lung Cancer Trials Ask AI to find trials
CompletedNot applicableNCT07224737
Official study title

Liquid Biopsy Using Exosomal miRNA Enables Risk Stratification of Potential Metastasis in Patients With Intrahepatic Cholangiocarcinoma.

Study summary

Occult metastasis at the time of surgery is a major driver of poor outcomes in intrahepatic cholangiocarcinoma (ICC), yet reliable preoperative biomarkers to identify such patients are lacking. The EXOMIC study aims to develop and validate a circulating exosomal microRNA (exo-miRNA)-based liquid biopsy assay to detect occult metastasis preoperatively in patients with resectable ICC.

Ask AI to explain this study
Start here

Key things to know

Main goalNot specified

This describes the study’s primary purpose.

What is being studiedEXOMIC small RNA sequencing and EXOMIC assay (qRT-PCR validation)

The study team can explain what participation involves.

Who it may be forEarly-stage or resectable

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Mar 13, 2026 · Source: ClinicalTrials.gov

Is enrollment open?Completed

Ask the study team to confirm whether enrollment is open.

What kind of study?Not applicable

Observational

Where is it offered?1 U.S. location

Locations may change over time.

Who runs it?City of Hope Medical Center

Study sponsor

01
Study overview

What this study is about

Purpose
Not specified
Study type
Observational
Phase
Not applicable
Sponsor
City of Hope Medical Center
Interventions being studied
Diagnostic Test: EXOMIC small RNA sequencing; Diagnostic Test: EXOMIC assay (qRT-PCR validation)
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Disease setting
Early-stage or resectable→
Treatment approach
Surgery→
Study topics
Before surgery (neoadjuvant)→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • Histologically confirmed ICC (clinical stage I-III).
  • Undergoing curative-intent hepatectomy.
  • Availability of preoperative pasma or serum sample (≥200 µL).
  • Standard staging imaging completed per institutional protocol.
  • Written informed consent.
Reasons someone may not be able to joinExclusion criteria
  • Extrahepatic cholangiocarcinoma or gallbladder cancer.
  • Synchronous non-ICC malignancy.
  • Inadequate clinical follow-up.
  • Inability to consent.

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • City of Hope Medical CenterDuarte, California

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Mar 13, 2026. Always confirm current availability with the study team.

View original record ↗